Extent of demyelination is decreased following NgR knock down. by Fereshteh Pourabdolhossein (624998)

Biosynthetic flux decreases with biosynthetic ability and increases with nutrient flexibility. by Tugce Bilgin (154647)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Decreased HbNO production in HbE/ß-thal subjects. by Attaphon Chamchoi (5774669)

Resveratrol treatment decreases SIRT1 and SIRT2 levels. by Mehtap Kilic Eren (591048)

Activation of NMDA receptors with D-serine obviously limited the decrease of p-CREB in the hippocampus of the surviving LPS-treated mice. by Shuibing Zhang (4336402)

Neuronal differentiation is significantly decreased by age in the mouse hippocampal DG. by Joana Gil-Mohapel (462002)

Temporal distributions of inscriptions and occupations using uniform 50-years-long timeblocks. by Vojtěch Kaše (6156971)

HDM exposure results in increased MIP-2 and decreased IFNα and IL-13. by Jennifer A. Phan (535730)

“…HDM exposure increased bronchoalveolar lavage MIP-2 (A), and decreased IFNα (B) and IL13 (C). There was no effect of HDM exposure on BAL protein (D), nor were there any effects of HRV-1B infection alone, or combined effects of HDM exposure and HRV-1B infection on any of these parameters. * indicates a significant difference between groups. …”

Cilostazol decreases OC formation and bone resorption induced by RANKL. by Ke Ke (583325)

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Propofol increased the number of the hippocampal pyramidal neurons and decreased the expression of the LC3-II protein and the number of lysosomes and autophagosomes in the ischemic... by Derong Cui (326839)

“…<p>I/R was induced by 2-vessel occlusion. Propofol 10, 50, or 100 mg/kg was administrated intraperitoneally and 3-MA (600 nM) was administered intracerebroventricularly 10 min after the onset of ischemia. (1) Sham-operated group (control group, Cont); (2) I/R group; (3) I/R+ 3-MA 600 nmol group; (4) I/R + propofol 10 mg/kg group; (5) I/R + propofol 50 mg/kg group; (6) I/R + propofol 100 mg/kg group; (7) I/R + vehicle (intralipid, 100 mg/kg) group. …”

SPARC overexpression promotes AC invasion by decreasing type IV collagen levels in the BM. by Meghan A. Morrissey (2541352)

Treatment with con-G showed improved neurological scoring and decreased peri-infarct Ca²⁺ microdeposits. by Rashna Balsara (714796)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Reduced RabGEF1 expression decreases NGF-induced TrkA phosphorylation but not TrkA internalization. by See-Ying Tam (828866)

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

PADK decreases intra- and extracellular 6E10 staining in APPswe/PS1ΔE9 (APP-PS1) mice of 20–22 months. by David Butler (349975)